Primary Site >> Biliary tract Cancer

Gene >> MAP2K1

Journal: Int J Oncol. 2006 Apr;28(4):915-21.
Title: The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines.
Author: Miyata, Hideki|Sasaki, Tamito|Kuwahara, Kenichi|Serikawa, Masahiro|Chayama, Kazuaki
PMID: 16525641
Journal: Virchows Arch. 2006 Jun;448(6):776-87.
Title: Cystic cholangiomas after transplantation of pancreatic islets into the livers of diabetic rats.
Author: Evert, Matthias|Schildhaus, Hans-Ulrich|Schneider-Stock, Regine|Dombrowski, Frank
PMID: 16601979
Journal: J Surg Res. 2006 Nov;136(1):78-84. Epub 2006 Sep 1.
Title: Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met.
Author: Leelawat, Kawin|Leelawat, Surang|Tepaksorn, Panada|Rattanasinganchan, Panthip|Leungchaweng, Anicha|Tohtong, Rutaiwan|Sobhon, Prasert
PMID: 16950403
Journal: World J Gastroenterol. 2007 Mar 14;13(10):1561-8.
Title: Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion.
Author: Leelawat, Kawin|Leelawat, Surang|Narong, Siriluck|Hongeng, Suradej
PMID: 17461449
Journal: Expert Rev Gastroenterol Hepatol. 2011 Oct;5(5):579-81.
Title: Inhibitor of MEK1/2, selumetinib, for biliary tract cancer.
Author: Furuse, Junji|Nagashima, Fumio
PMID: 21910575
Journal: Ann Surg Oncol. 2014 Nov;21(12):3827-34.
Title: Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.
Author: Zhu, Andrew X|Borger, Darrell R|Kim, Yuhree|Cosgrove, David|Ejaz, Aslam|Alexandrescu, Sorin|Groeschl, Ryan Thomas|Deshpande, Vikram|Lindberg, James M|Ferrone, Cristina|Sempoux, Christine|Yau, Thomas|Poon, Ronnie|Popescu, Irinel|Bauer, Todd W|Gamblin, T Cl
PMID: 24889489
Journal: Oncotarget. 2016 Feb 2;7(5):5306-12.
Title: Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors.
Author: Ahn, Daniel H|Ozer, Hatice Gulcin|Hancioglu, Baris|Lesinski, Gregory B|Timmers, Cynthia|Bekaii-Saab, Tanios
PMID: 26683364
Journal: BMC Cancer. 2016 Feb 24;16:153.
Title: A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.
Author: Bridgewater, John|Lopes, Andre|Beare, Sandra|Duggan, Marian|Lee, Dymphna|Ricamara, Maravic|McEntee, Delyth|Sukumaran, Ajithkumar|Wasan, Harpreet|Valle, Juan W
PMID: 26912134
Journal: Mol Cancer Ther. 2017 Feb;16(2):344-356.
Title: Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.
Author: Talbert, Erin E|Yang, Jennifer|Mace, Thomas A|Farren, Matthew R|Farris, Alton B|Young, Gregory S|Elnaggar, Omar|Che, Zheng|Timmers, Cynthia D|Rajasekera, Priyani|Maskarinec, Jennifer M|Bloomston, Mark|Bekaii-Saab, Tanios|Guttridge, Denis C|Lesinski, Grego
PMID: 27811010
Journal: Cancer Cell Int. 2017 Sep 26;17:85.
Title: Blocking ERK1/2 signaling impairs TGF-beta1 tumor promoting function but enhances its tumor suppressing role in intrahepatic cholangiocarcinoma cells.
Author: Sritananuwat, Phaijit|Sueangoen, Natthaporn|Thummarati, Parichut|Islam, Kittiya|Suthiphongchai, Tuangporn
PMID: 28959141
Journal: Cancer Sci. 2018 Jan;109(1):215-224.
Title: Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine.
Author: Ikeda, Masafumi|Ioka, Tatsuya|Fukutomi, Akira|Morizane, Chigusa|Kasuga, Akiyoshi|Takahashi, Hideaki|Todaka, Akiko|Okusaka, Takuji|Creasy, Caretha L|Gorman, Shelby|Felitsky, Daniel J|Kobayashi, Mikiro|Zhang, Fanghong|Furuse, Junji
PMID: 29121415
Journal: Invest New Drugs. 2018 May 22. pii: 10.1007/s10637-018-0600-2.
Title: Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.
Author: Finn, R S|Ahn, D H|Javle, M M|Tan, B R Jr|Weekes, C D|Bendell, J C|Patnaik, A|Khan, G N|Laheru, D|Chavira, R|Christy-Bittel, J|Barrett, E|Sawyer, M B|Bekaii-Saab, Tanios S
PMID: 29785570